Skip to content

Released Mar 5, 2015, after the close

10-K filed Mar 5, 2015, 64 days after period end · 0001390478-15-000012

Q4 2014 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$3.20Mderived+122.5% vs Q4 2013+47.0% vs Q1 2014
Net Income-$7.96MderivedN/M vs Q4 2013N/M vs Q1 2014
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$5,701,000N/M
Operating Cash Flowderived-$10,734,000N/M
Free Cash Flowderived-$10,743,000N/M
Margins · derived
Operating margin-178.4%+309.0 pt vs Q4 2013
Net margin-249.0%+135.1 pt vs Q4 2013

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2014derived from reported figuresQ4 2013Q4 2012Q4 2011derived from reported figures
Revenue$3.20M$1.44M$1.44M—
Net Income-$7.96M-$5.52M-$19.68M$1.59M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR